Scientific Advisory Committee
The Scientific Advisory Committee, or SAC, is an independent body within 51²è¹Ý. It is one of 51²è¹Ý's core governance groups alongside the Board, Investors Council and Joint Coordination Group.
How they work
The SAC provides scientific support, advice and challenge to the 51²è¹Ý Leadership and Board on a range of scientific issues related to vaccine research and development and manufacturing to support the effective implementation of 51²è¹Ý’s strategic objectives.
SAC Members
- Professor Alash'le Abimiku  – International Research Center of Excellence, Institute of Human Virology, Nigeria
- Associate Professor Ifedayo Adetifa, Independent Public Health Expert, Kenya
- Dr Vincent Ahonkhai – Gwynedd Consultancy Group, LLC, USA
- Emeritus Professor Vineeta Bal  – Indian Institute of Science Education and Research, Pune, India
- Dr Rick A. Bright  – Bright Global Health, USA
- Dr Paula Bryant  – National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
- Assistant Professor Yunlong Cao – Peking University, China
- Dr Peter Dull  – Bill & Melinda Gates Foundation, USA
- Professor Azra Ghani  – Imperial College London, United Kingdom
- Dr Paula Goldin  – Senior Medical Director PPD, Thermo Fisher, Argentina
- Dr Rebecca Grais  – Pasteur Network, France
- Professor Glenda E. Gray  – South African Medical Research Council, South Africa
- Dr Beth-Ann Griswold Coller  – Consultant, BCG Vaccine Consulting LLC, USA
- Dr Ana Maria Henao-Restrepo – World Health Organization, Switzerland
- Professor Ken J. Ishii  – International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Japan
- Professor Amine Kamen  – McGill University, Canada
- Professor Michael King (Acting Chair)  – University of Virginia, USA
- Professor Kevin Kee-Jong Hong – Korea mRNA Vaccine Initiative, Korea
- Dr Gary Kobinger – Galveston National Laboratory/Institute for Drug Discovery, University of Texas Medical Branch, USA
- Dr Phil Krause  – World Health Organization, USA
- Dr Luciana C. C. Leite – Head of Recombinant BCG Laboratory, Instituto Butantan, Brazil,
- Professor Marc Lipsitch  – Harvard T.H. Chan School of Public Health, USA
- Mr Dominique Maugeais  – RH Solutions, France
- Dr Placide Mbala-Kingebeni  – Head of Epidemiology and Global Health Department, Institut National de Recherche Biomedicale, Democratic Republic of Congo
- Mr Sly Ngoni Mutyavaviri  – Senior GMP Inspector, Medicines Control Authority of Zimbabwe and SADC Medicines Regulatory Harmonisation Inspections Coordinator, SADC Medicines Regulatory Harmonisation, Zimbabwe
- Dr Laura Palomares Aguilera (Acting Chair)  – Instituto de BiotecnologÃa, Universidad Nacional Autónoma de México (UNAM), Mexico
- Dr Peter Paradiso  – Paradiso Biologics Consulting, LLC, USA
- Professor Stanley Plotkin  – University of Pennsylvania, USA
- Dr Marie-José Quentin-Millet  – MJQuentinMillet Consulting, France
- Professor Rino Rappuoli  – Fondazione Biotecnopolo di Siena, Italy
- Dr Andre Siqueira  – Public Health Researcher, Fundação Oswaldo Cruz (Fiocruz), Brazil
- Dr Lynda Stuart  – Institute for Protein Design, USA
- Professor Linfa Wang  – Duke-NUS Medical School, Singapore
- Professor George Warimwe  – KEMRI-Wellcome Trust Research Programme, Kenya and University of Oxford, United Kingdom
Joint Coordination Group
Our Joint Coordination Group, or JCG, is a roundtable of independent institutions with an interest in seeing 51²è¹Ý-funded vaccines successfully developed and deployed in an outbreak.
Portfolio Strategy and Management Board
The PSMB is the decision-making body accountable for identification, selection, management and evaluation of 51²è¹Ý’s R&D and Manufacturing portfolio.
